vestibИзвестия Национальной академии наук Беларуси. Серия биологических наукProceedings of the National Academy of Sciences of Belarus, Biological Series1029-89402524-230XThe Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1029-8940-2022-67-4-426-432vestib-841Research ArticleОБЗОРЫREVIEWSМолнупиравир как перспективное пролекарственное средство для терапии COVID-19Molnupiravir as a promising prodrug agent for therapy of COVID-19БиричевскаяЛ. Л.BirichevskayaL. L.

Биричевская Лариса Леонидовна – канд. биол. наук, доцент, вед. науч. сотрудник

ул. Купревича, 2, 220141, г. Минск

Larisa L. Birichevskaya – Ph. D (Biol.), Associate Professor, Leading Researcher

2, Kuprevich Str., 220141, Minsk

larbir@mail.ruКвасюкЕ. И.KvasyukE. I.

Квасюк Евгений Иванович – д-р хим. наук, профессор

ул. Долгобродская, 23/1, 220070, г. Минск

Evgeniy I. Kvasyuk – D. Sc. (Chem.), Professor

23/1, Dolgobrodskaya Str., 220070, Minsk

ekvasyuk@inbox.ruЗинченкоА. И.ZinchenkoA. I.

Зинченко Анатолий Иванович – член-корреспондент, д-р биол. наук, профессор, заведующий лабораторией

ул. Купревича, 2, 220141, г. Минск

Anatoliy I. Zinchenko – Corresponding Member, D. Sc. (Biol.), Professor, Head of the Laboratory

 

zinch@mbio.bas-net.byИнститут микробиологии НАН БеларусиInstitute of Microbiology of the National Academy of Sciences of BelarusМеждународный государственный экологический институт им. А. Д. Сахарова БГУInternational Sakharov Environmental Institute of Belarusian State University202202112022674426432Copyright © Биричевская Л.Л., Квасюк Е.И., Зинченко А.И., 20222022Биричевская Л.Л., Квасюк Е.И., Зинченко А.И.Birichevskaya L.L., Kvasyuk E.I., Zinchenko A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestibio.belnauka.by/jour/article/view/841

Непрекращающаяся пандемия COVID-19, сопровождающаяся появлением все новых антигенных вариантов возбудителя, делает проблематичным подход, основанный на применении для борьбы с SARS-CoV-2 только профилактических вакцин. Это обстоятельство обусловливает настоятельную необходимость скорейшего поиска и создания химиопрепаратов прямого противовирусного действия.

В настоящей мини-обзорной статье приводится информация о химических и ферментативных методах получения молнупиравира, считающегося на сегодняшний день одним из самых перспективных лекарственных средств для терапии COVID-19. В заключении литературного обзора предлагается использовать для терапии COVID-19 не сам молнупиравир, а его липидсодержащий аналог. В связи с этим авторы сообщают о синтезе ими с помощью бактериальной фосфолипазы D 5ʹ-димиристоильного производного N4-гидроксицитидина – соединения, которое, как предполагается, более эффективно, чем молнупиравир, в отношении ингибирования репликации SARS-CoV-2.

The ongoing COVID-19 pandemic accompanied by the emergence of new successive pathogenic variants makes problematic the prospects of the approach based on application of exclusively prophylactic vaccines to combat SARSCoV-2. This reason motivated the urgent need in search and development of chemical formulas showing direct antiviral action.

The present mini-review provides data on chemical and enzymatic methods of producing molnupiravir regarded so far as one of the most effective pharmaceuticals for treatment of COVID-19. In conclusion of the literature survey it is suggested to administer lipid-containing analog instead of molnupiravir in COVID-19 therapeutic protocols. In this respect the authors reported the successful synthesis catalyzed by bacterial phospholipase D of 5′-dimyristoyl derivative of N4-hydroxycytidine – the compound allegedly more efficient than molnupiravir in inhibiting SARS-CoV-2 replication.

пандемия COVID-19химиотерапиямодифицированный нуклеозидN4-гидроксицитидинхимический и ферментативный синтез молнупиравирафосфолипаза DтрансфосфатидилированиеCOVID-19 pandemicchemotherapymodified nucleosideN4-hydroxycytidinechemical and enzymatic synthesis of molnupiravirphospholipase DtransphosphatidylationReferencesCOVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University Available at: https://github.com/CSSEGISandData/COVID-19 (аccessed 05.06.2022).COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University Available at: https://github.com/CSSEGISandData/COVID-19 (аccessed 05.06.2022).Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y. [et al.]. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: a meta-analysis. Annals of Medicine, 2022, vol. 54, no. 1, pp. 516– 523. https://doi.org/10.1080/07853890.2022.2034936Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y. [et al.]. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: a meta-analysis. Annals of Medicine, 2022, vol. 54, no. 1, pp. 516– 523. https://doi.org/10.1080/07853890.2022.2034936Dutta A., Roy A., Roy L., Chattopadhyay S., Chatterjee S. Immune response and possible therapeutics in COVID-19. RSC Advances, 2021, vol. 11, no. 2, pp. 960–977. https://doi.org/10.1039/D0RA08901JDutta A., Roy A., Roy L., Chattopadhyay S., Chatterjee S. Immune response and possible therapeutics in COVID-19. RSC Advances, 2021, vol. 11, no. 2, pp. 960–977. https://doi.org/10.1039/D0RA08901JMehellou Y., Rattan H. S., Balzarini J. The ProTide prodrug technology: from the concept to the clinic. Journal of Medicinal Chemistry, 2018, vol. 61, no. 6, pp. 2211–2226. https://doi.org/10.1021/acs.jmedchem.7b00734Mehellou Y., Rattan H. S., Balzarini J. The ProTide prodrug technology: from the concept to the clinic. Journal of Medicinal Chemistry, 2018, vol. 61, no. 6, pp. 2211–2226. https://doi.org/10.1021/acs.jmedchem.7b00734Toots M., Yoon J. J., Cox R. M., Hart M., Sticher Z. M., Makhsous N. [et al.]. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine, 2019, vol. 11, no. 515, art. eaax5866. https://doi.org/10.1126/scitranslmed.aax5866Toots M., Yoon J. J., Cox R. M., Hart M., Sticher Z. M., Makhsous N. [et al.]. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine, 2019, vol. 11, no. 515, art. eaax5866. https://doi.org/10.1126/scitranslmed.aax5866Toots M., Yoon J. J., Hart M., Natchus M. G., Painter G. R., Plemper R. K. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational Research, 2020, vol. 218, pp. 16–28. https:// doi.org/10.1016/j.trsl.2019.12.002Toots M., Yoon J. J., Hart M., Natchus M. G., Painter G. R., Plemper R. K. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational Research, 2020, vol. 218, pp. 16–28. https:// doi.org/10.1016/j.trsl.2019.12.002Cross R. Merck & Co. joins race for COVID-19 vaccines and therapies. Chemical and Engineering News, 2020, vol. 98, no. 23, p. 12.Cross R. Merck & Co. joins race for COVID-19 vaccines and therapies. Chemical and Engineering News, 2020, vol. 98, no. 23, p. 12.Sheahan T. P., Sims A. C., Zhou S., Graham R. L., Pruijssers A. J., Agostini M. L. [et al.]. An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science Translational Medicine, 2020, vol. 12, art. 541. https://doi.org/10.1126/scitranslmed.abb5883Sheahan T. P., Sims A. C., Zhou S., Graham R. L., Pruijssers A. J., Agostini M. L. [et al.]. An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science Translational Medicine, 2020, vol. 12, art. 541. https://doi.org/10.1126/scitranslmed.abb5883Hernandez-Santiago B. I., Beltran T., Stuyver L., Chu C. K., Schinazi R. F. Metabolism of the anti-hepatitis C virus nucleoside β-d-N 4-hydroxycytidine in different liver cells. Antimicrobial Agents and Chemotherapy, 2004, vol. 48, no. 12, pp. 4636–4642. https://doi.org/10.1128/AAC.48.12.4636-4642.2004Hernandez-Santiago B. I., Beltran T., Stuyver L., Chu C. K., Schinazi R. F. Metabolism of the anti-hepatitis C virus nucleoside β-d-N 4-hydroxycytidine in different liver cells. Antimicrobial Agents and Chemotherapy, 2004, vol. 48, no. 12, pp. 4636–4642. https://doi.org/10.1128/AAC.48.12.4636-4642.2004Painter G. R., Bowen R. A., Bluemling G. R., DeBergh J., Edpuganti V., Gruddanti P. R. [et al.]. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Research, 2019, vol. 171, art. 104597. https://doi.org/10.1016/j.antiviral.2019.104597Painter G. R., Bowen R. A., Bluemling G. R., DeBergh J., Edpuganti V., Gruddanti P. R. [et al.]. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Research, 2019, vol. 171, art. 104597. https://doi.org/10.1016/j.antiviral.2019.104597Zarenezhad E., Marzi M. Review on molnupiravir as a promising oral drug for the treatment of COVID-19. Medicinal Chemistry Research, 2022, vol. 31, no. 2, pp. 232–243. https://doi.org/10.1007/s00044-021-02841-3Zarenezhad E., Marzi M. Review on molnupiravir as a promising oral drug for the treatment of COVID-19. Medicinal Chemistry Research, 2022, vol. 31, no. 2, pp. 232–243. https://doi.org/10.1007/s00044-021-02841-3Agostini M. L., Pruijssers A. J., Chappell J. D., Gribble J., Lu X., Andres E. L. [et al.]. Small-molecule antiviral β-d-N 4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. Journal of Virology, 2019, vol. 93, no. 24, art. e01348–19. https://doi.org/10.1128/JVI.01348-19Agostini M. L., Pruijssers A. J., Chappell J. D., Gribble J., Lu X., Andres E. L. [et al.]. Small-molecule antiviral β-d-N 4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. Journal of Virology, 2019, vol. 93, no. 24, art. e01348–19. https://doi.org/10.1128/JVI.01348-19Reynard O., Nguyen X. N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V. E. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses, 2015, vol. 7, no. 12, pp. 6233–6240. https://doi.org/10.3390/v7122934Reynard O., Nguyen X. N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V. E. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses, 2015, vol. 7, no. 12, pp. 6233–6240. https://doi.org/10.3390/v7122934Fischer W., Eron J. J., Holman W., Cohen M. S., Fang L., Szewczyk L. J. [et al.]. Molnupiravir an oral antiviral treatment for COVID-19. medRxiv, 2021. https://doi.org/10.1101/2021.06.17.21258639Fischer W., Eron J. J., Holman W., Cohen M. S., Fang L., Szewczyk L. J. [et al.]. Molnupiravir an oral antiviral treatment for COVID-19. medRxiv, 2021. https://doi.org/10.1101/2021.06.17.21258639Painter W. P., Holman W., Bush J. A., Almazedi F., Malik H., Eraut N. C. J. E., Morin M. J., Szewczyk L. J., Painter G. R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 2021, vol. 65, art. e02428–20. https://doi.org/10.1128/AAC.02428-20Painter W. P., Holman W., Bush J. A., Almazedi F., Malik H., Eraut N. C. J. E., Morin M. J., Szewczyk L. J., Painter G. R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 2021, vol. 65, art. e02428–20. https://doi.org/10.1128/AAC.02428-20Zarenezhad E., Behrouz S., Farjam M., Rad M. N. S. A mini review on discovery and synthesis of remdesivir as an effective and promising drug against COVID-19. Russian Journal of Bioorganic Chemistry, 2021, vol. 47, no. 3, pp. 609–621. https://doi.org/10.1134/S1068162021030183Zarenezhad E., Behrouz S., Farjam M., Rad M. N. S. A mini review on discovery and synthesis of remdesivir as an effective and promising drug against COVID-19. Russian Journal of Bioorganic Chemistry, 2021, vol. 47, no. 3, pp. 609–621. https://doi.org/10.1134/S1068162021030183Singh A. K., Singh A., Singh R., Misra A. Molnupiravir in COVID-19: a systematic review of literature. Diabetes and Metabolic Syndrome, 2021, vol. 15, no. 6, art. 102329. https://doi.org/10.1016/j.dsx.2021.102329Singh A. K., Singh A., Singh R., Misra A. Molnupiravir in COVID-19: a systematic review of literature. Diabetes and Metabolic Syndrome, 2021, vol. 15, no. 6, art. 102329. https://doi.org/10.1016/j.dsx.2021.102329Khoo S. H., Fitzgerald R., Fletcher T., Ewings S., Jaki T., Lyon R. [et al.]. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. Journal of Antimicrobial Chemotherapy, 2021, vol. 76, no. 12, pp. 3286–3295. https://doi.org/10.1101/2021.05.03.21256309Khoo S. H., Fitzgerald R., Fletcher T., Ewings S., Jaki T., Lyon R. [et al.]. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. Journal of Antimicrobial Chemotherapy, 2021, vol. 76, no. 12, pp. 3286–3295. https://doi.org/10.1101/2021.05.03.21256309Kabinger F., Stiller C., Schmitzová J., Dienemann C., Kokic G., Hillen H. S., Höbartner C., Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature Structural and Molecular Biology, 2021, vol. 28, no. 9, pp. 740– 746. https://doi.org/10.1038/s41594-021-00651-0Kabinger F., Stiller C., Schmitzová J., Dienemann C., Kokic G., Hillen H. S., Höbartner C., Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature Structural and Molecular Biology, 2021, vol. 28, no. 9, pp. 740– 746. https://doi.org/10.1038/s41594-021-00651-0Crotty S., Cameron C. E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proceedings of the National Academy of Sciences of the United States of America, 2001, vol. 98, no. 12, pp. 6895–6900. https://doi.org/10.1073/pnas.111085598Crotty S., Cameron C. E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proceedings of the National Academy of Sciences of the United States of America, 2001, vol. 98, no. 12, pp. 6895–6900. https://doi.org/10.1073/pnas.111085598Gordon C. J., Tchesnokov E. P., Schinazi R. F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. Journal of Biological Chemistry, 2021, vol. 297, no. 1, art. 100770. https://doi.org/10.1016/j.jbc.2021.100770Gordon C. J., Tchesnokov E. P., Schinazi R. F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. Journal of Biological Chemistry, 2021, vol. 297, no. 1, art. 100770. https://doi.org/10.1016/j.jbc.2021.100770Malone B., Campbell E. A. Molnupiravir: coding for catastrophe. Nature Structural & Molecular Biology, 2021, vol. 28, pp. 706–708. https://doi.org/10.1038/s41594-021-00657-8Malone B., Campbell E. A. Molnupiravir: coding for catastrophe. Nature Structural & Molecular Biology, 2021, vol. 28, pp. 706–708. https://doi.org/10.1038/s41594-021-00657-8N4-hydroxycytidine and derivatives and anti-viral uses related thereto: pat. WO2019113462 A1, IPC C 07 H 19/06 / G. R. Painter [et al.], 2019.N4-hydroxycytidine and derivatives and anti-viral uses related thereto: pat. WO2019113462 A1, IPC C 07 H 19/06 / G. R. Painter [et al.], 2019.Steiner A., Znidar D., Ötvös S. B., Snead D. R., Dallinger D., Kappe C. O. A high-yielding synthesis of EIDD‐2801 from uridine. European Journal of Organic Chemistry, 2020, vol. 43, pp. 6736–6739. https://doi.org/10.1002/ejoc.202001340Steiner A., Znidar D., Ötvös S. B., Snead D. R., Dallinger D., Kappe C. O. A high-yielding synthesis of EIDD‐2801 from uridine. European Journal of Organic Chemistry, 2020, vol. 43, pp. 6736–6739. https://doi.org/10.1002/ejoc.202001340Hu T., Xie Y., Liu Y., Xue H, Zhu F., A. Aisa H., Shen J. Convenient and cost efficient route suitable for one-pot synthesis of molnupiravir. ChemRxiv, 2021. https://doi.org/10.26434/chemrxiv.14208206.v1Hu T., Xie Y., Liu Y., Xue H, Zhu F., A. Aisa H., Shen J. Convenient and cost efficient route suitable for one-pot synthesis of molnupiravir. ChemRxiv, 2021. https://doi.org/10.26434/chemrxiv.14208206.v1Gopalsamuthiram V., Kadam A. L., Noble J., Snead D., Williams C., Jamison T. F. [et al.]. Towards a practical, nonenzymatic process for molnupiravir from cytidine. ChemRxiv, 2021. https://doi.org/10.26434/chemrxiv.14738109.v1Gopalsamuthiram V., Kadam A. L., Noble J., Snead D., Williams C., Jamison T. F. [et al.]. Towards a practical, nonenzymatic process for molnupiravir from cytidine. ChemRxiv, 2021. https://doi.org/10.26434/chemrxiv.14738109.v1Sheldon R. A., Brady D. Green chemistry, biocatalysis, and the chemical industry of the future. Chemsuschem, 2022. Art. e202102628. https://doi.org/10.1002/cssc.202102628Sheldon R. A., Brady D. Green chemistry, biocatalysis, and the chemical industry of the future. Chemsuschem, 2022. Art. e202102628. https://doi.org/10.1002/cssc.202102628Benkovics T., McIntosh J., Silverman S., Kong J., Maligres P., Itoh T. [et al.]. Evolving to an ideal synthesis of molnupiravir, an investigational treatment for COVID-19. ChemRxiv, 2020. https://doi.org/10.26434/chemrxiv.13472373.v1Benkovics T., McIntosh J., Silverman S., Kong J., Maligres P., Itoh T. [et al.]. Evolving to an ideal synthesis of molnupiravir, an investigational treatment for COVID-19. ChemRxiv, 2020. https://doi.org/10.26434/chemrxiv.13472373.v1Vasudevan N., Ahlqvist G. P., McGeough C. P., Paymode D. J., Cardoso F. S. P., Lucas T. [et al.]. A concise route to MK-4482 (EIDD-2801) from cytidine. Chemical Communications, 2020, vol. 56, no. 87, pp. 13363–13364. https://doi.org/ 10.1039/D0CC05944Vasudevan N., Ahlqvist G. P., McGeough C. P., Paymode D. J., Cardoso F. S. P., Lucas T. [et al.]. A concise route to MK-4482 (EIDD-2801) from cytidine. Chemical Communications, 2020, vol. 56, no. 87, pp. 13363–13364. https://doi.org/ 10.1039/D0CC05944Ahlqvist G. P., McGeough C. P., Senanayake C., Armstrong J. D., Yadaw A., Roy S., Ahmad S., Snead D. R., Jamison T. F. Progress toward a large-scale synthesis of molnupiravir (MK-4482, EIDD-2801) from cytidine. ACS Omega, 2021, vol. 6, no. 15, pp. 10396–10402. https://doi.org/10.1021/acsomega.1c00772Ahlqvist G. P., McGeough C. P., Senanayake C., Armstrong J. D., Yadaw A., Roy S., Ahmad S., Snead D. R., Jamison T. F. Progress toward a large-scale synthesis of molnupiravir (MK-4482, EIDD-2801) from cytidine. ACS Omega, 2021, vol. 6, no. 15, pp. 10396–10402. https://doi.org/10.1021/acsomega.1c00772Paymode D. J., Vasudevan N., Ahmad S., Kadam A. L., Cardoso F. S. P., Burns J., Cook D. W., Stringham R. W., Snead D. Toward a practical, two-step process for molnupiravir from cytidine. ChemRxiv, 2021. https://doi.org/10.26434/ chemrxiv.13550537.v1Paymode D. J., Vasudevan N., Ahmad S., Kadam A. L., Cardoso F. S. P., Burns J., Cook D. W., Stringham R. W., Snead D. Toward a practical, two-step process for molnupiravir from cytidine. ChemRxiv, 2021. https://doi.org/10.26434/ chemrxiv.13550537.v1Burke A. J., Birmingham W. R., Zhuo Y., Thorpe T. W., Zucoloto da Costa B., Crawshaw R. [et al.]. An engineered cytidine deaminase for biocatalytic production of a key intermediate of the Covid-19 antiviral Molnupiravir. Journal of the American Chemical Society, 2022, vol. 144, no. 9, pp. 3761–3765. https://doi.org/10.1021/jacs.1c11048Burke A. J., Birmingham W. R., Zhuo Y., Thorpe T. W., Zucoloto da Costa B., Crawshaw R. [et al.]. An engineered cytidine deaminase for biocatalytic production of a key intermediate of the Covid-19 antiviral Molnupiravir. Journal of the American Chemical Society, 2022, vol. 144, no. 9, pp. 3761–3765. https://doi.org/10.1021/jacs.1c11048Birichevskaya L. L., Zinchenko A. I., Kvasyuk E. I., Khanchevskii M. A., Doroshevich A. K. Synthesis of a phosphatidyl derivative β-D-N4-hydroxycytidine using microbial phospholipase D. Tekhnologiya organicheskikh veshchestv: materialy 86-i nauchno-tekhnicheskoi konferentsii professorsko-prepodavatel’skogo sostava, nauchnykh sotrudnikov i aspirantov (Minsk, 31 yanvarya–12 fevralya 2022 goda) [Technology of organic substances: materials of the 86th scientific and technical conference of faculty, researchers and graduate students (Minsk, January 31–February 12, 2022)]. Minsk, 2022, pp. 265–267 (in Russian).Birichevskaya L. L., Zinchenko A. I., Kvasyuk E. I., Khanchevskii M. A., Doroshevich A. K. Synthesis of a phosphatidyl derivative β-D-N4-hydroxycytidine using microbial phospholipase D. Tekhnologiya organicheskikh veshchestv: materialy 86-i nauchno-tekhnicheskoi konferentsii professorsko-prepodavatel’skogo sostava, nauchnykh sotrudnikov i aspirantov (Minsk, 31 yanvarya–12 fevralya 2022 goda) [Technology of organic substances: materials of the 86th scientific and technical conference of faculty, researchers and graduate students (Minsk, January 31–February 12, 2022)]. Minsk, 2022, pp. 265–267 (in Russian).

The authors declare that there are no conflicts of interest present.